Lavandula angustifolia is one of the most popular medicinal plants, and is a rich source of bioactive compounds. Most of the studies on lavender have focused on its essential oil and its use as a sleep aid, calmative, fragrant, insect repellant and flavoring agent. This work is aimed at investigating, for the first time, the potential role of L. angustifolia in the management of metabolic syndrome (MetS), one of the major and escalating public-health and clinical challenges worldwide. Herein, the aerial parts of L. angustifolia, collected in June 2021 in the “Parco Nazionale del Pollino”, Southern Italy, were subjected to extraction by maceration with ethanol. Then, the total extract was partitioned with solvents at different polarities such as n-hexane, dichloromethane and ethyl acetate. The extract and fractions were evaluated for their ability to inhibit alpha-glucosidase as well as lipase. The ethanol extract remarkably inhibited α-glucosidase and lipase (IC50 of 2.55 and 30.50 µg/mL, respectively) better than the positive control acarbose and orlistat (IC50 of 35.51 and 37.12 µg/mL, respectively). The most active fraction was dichloromethane with an IC50 of 14.67 and 17.64 µg/mL, against α-glucosidase and lipase, respectively. Taking into account the obtained results, L. angustifolia could be used for the formulation of new products; however, further preclinical studies will be needed to confirm its in vivo efficacy, as well as to prove the safety of the tested extracts and fractions.

In Vitro inhibitory effects on pancreatic lipase and α-glucosidase activity by extracts and fractions of Lavandula angustifolia L. from Southern Italy

Rosa Tundis;Anna Rita Cappello;Monica Rosa Loizzo
2022-01-01

Abstract

Lavandula angustifolia is one of the most popular medicinal plants, and is a rich source of bioactive compounds. Most of the studies on lavender have focused on its essential oil and its use as a sleep aid, calmative, fragrant, insect repellant and flavoring agent. This work is aimed at investigating, for the first time, the potential role of L. angustifolia in the management of metabolic syndrome (MetS), one of the major and escalating public-health and clinical challenges worldwide. Herein, the aerial parts of L. angustifolia, collected in June 2021 in the “Parco Nazionale del Pollino”, Southern Italy, were subjected to extraction by maceration with ethanol. Then, the total extract was partitioned with solvents at different polarities such as n-hexane, dichloromethane and ethyl acetate. The extract and fractions were evaluated for their ability to inhibit alpha-glucosidase as well as lipase. The ethanol extract remarkably inhibited α-glucosidase and lipase (IC50 of 2.55 and 30.50 µg/mL, respectively) better than the positive control acarbose and orlistat (IC50 of 35.51 and 37.12 µg/mL, respectively). The most active fraction was dichloromethane with an IC50 of 14.67 and 17.64 µg/mL, against α-glucosidase and lipase, respectively. Taking into account the obtained results, L. angustifolia could be used for the formulation of new products; however, further preclinical studies will be needed to confirm its in vivo efficacy, as well as to prove the safety of the tested extracts and fractions.
Lavandula angustifolia; ethanolic extract; fractionation; metabolic syndrome; lipase; alpha-glucosidase
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11770/341759
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact